Triall Announcements

Telegram closing announcement

As part of Triall's company winddown activities, our Telegram channel will be muted from today onwards (read only).

Please refer to the pinned messages above for additional context on Triall’s business closing and related activities.

Please be wary of scammers who claim to be Triall officials, we will never DM you first and we will not create a new Telegram chat or announcement channel.

For urgent matters, please reach out to us directly our official email address: [email protected]

Some additional FAQs:

Why did you inform us now?
https://t.me/triallcommunity/97201

Dit the team sell any tokens during the past period?
https://t.me/triallcommunity/97432

Did the team profit from TRL?
https://t.me/triallcommunity/97566

How have you used the ITO proceeds?
https://t.me/triallcommunity/97835

LBank de-listing announcement

In light of Triall’s company closing, $TRL will be de-listed from LBank at 12:00 UTC on March 4, 2024.

Please cancel your pending orders as soon as possible. For those who do not actively cancel their orders, LBank will cancel them uniformly.

LBank announcement: https://support.lbank.com/hc/en-gb/articles/29359877625241-LBank-Will-Delist-Certain-Trading-Pairs-2024-03-01

MEXC de-listing announcement 📢

In light of Triall’s company closing, $TRL will be de-listed from MEXC on March 2, 2024.

Please note:

- Once tokens are delisted, MEXC no longer supports their deposits and trading services. However, withdrawal services will remain available for 30 days after delisting. Please withdraw your assets in time to avoid any asset losses.

- The deposit service will be closed once the token is delisted. If you still deposit tokens to MEXC after the delisting, the platform will return your assets to the original sending address. This operation will cause some on-chain fees.

👉 MEXC announcement: https://www.mexc.com/support/articles/17827791513225

Triall Announcements pinned «What will happen to the company and Triall team? All Triall entities, both in The Netherlands and Estonia, will be closed according to local law and regulations. This process will take several months. The current team members will be available for limited…»

What will happen to the company and Triall team?

All Triall entities, both in The Netherlands and Estonia, will be closed according to local law and regulations. This process will take several months. The current team members will be available for limited time to facilitate this process and will then formally leave the company.


What will happen to the Telegram Channels?

We will leave the Telegram chat open for the next two weeks to address questions or comments from the community. After that period, per March 6, the Telegram chat will be muted and key announcements will be pinned for future reference. Please note that from this moment you will no longer be able to communicate with us via the main telegram group. Afterwards, anyone may send their questions or comments to our company e-mail: [email protected]


What will happen to the website and social media channels?

Similarly, the Triall website and Triall social media channels, including Twitter, Facebook, Medium, and YouTube, will be gradually closed over the coming weeks.


What will happen to the TRL token and liquidity?

The TRL token will remain tradeable on centralized and decentralized exchanges for limited time. It is anticipated that trading opportunities will gradually decrease. It is likely that the TRL token will lose (all, or part of) its value. Specifically:

- The liquidity on Uniswap and PancakeSwap will remain untouched, until the company is formally liquidated according to local regulations. It is therefore estimated that the liquidity will remain in the contracts for 6 more months.

- The TRL token will be delisted from both MEXC and LBank over time.

- The TRL token itself will continue to exist (is not actively burned), as per the nature of blockchain technology, but there will be no company or other entities (including the current Triall company) reasonably using or servicing the token.


Will Triall or its team members sell any tokens?

- Triall and its team members will not be selling any tokens.

- Triall has one outstanding obligation to a third party, originating from an agreement at the time of ITO, which is due mid-March this year and will be paid in TRL from the treasury wallet.

Triall Announcements pinned «Dear Triall community, Today, we regretfully must inform you that Triall will be closing its business operations. Over the past weeks, we have continued and initiated new conversations with venture capital firms and angel investors, with the help of our…»

Dear Triall community,

Today, we regretfully must inform you that Triall will be closing its business operations.

Over the past weeks, we have continued and initiated new conversations with venture capital firms and angel investors, with the help of our partners, advisors, and community members. In parallel, we have talked with multiple parties to negotiate a merger or acquisition. Unfortunately, none of these options have provided a viable path forward. Similarly, the community-proposed DAO structure, while much appreciated, does not provide sufficient financial, legal, and operational grounds for continuation.

We have explored, pursued, and exhausted all remaining options for ensuring continuation of Triall and utility token TRL. It has now become clear that the funding needed to sustain the company cannot be obtained in a timely manner, leaving us with no other choice than to close down our business and its operations.

We will use the coming period to gradually wind down various facets of the Triall business and token infrastructure, as is clarified in more detail in the following messages below.

This outcome undoubtedly comes as a big disappointment to all contributors and believers in Triall, including our core team, which has dedicated the past six years to building out the Triall mission and vision. We once more like to thank you for your contributions and hope for your understanding.

Kind regards,

The Triall team

Triall Announcements pinned «Dear Triall community, It is with a heavy heart that we must inform you about challenges Triall is facing in light of ongoing economic headwinds. Being an early-stage company, Triall is reliant on external funding to finance its operations and product…»

Dear Triall community,

It is with a heavy heart that we must inform you about challenges Triall is facing in light of ongoing economic headwinds.

Being an early-stage company, Triall is reliant on external funding to finance its operations and product development. Commercial sales from the eClinical platform alone are insufficient to sustain the company and have been slower than anticipated.

While we have previously been successful in raising external funding through equity sales and have used those funds to further build out the Triall ecosystem, we have not been able to secure further financing. A high-interest rate environment, recession fears, and the high-risk capital-intensive nature of our project have led to a situation where we find ourselves unable to raise sufficient capital to continue our current operations.

We installed various cost-saving measures throughout last year: Triall management has completely waived their management fees, employees have had their salaries reduced, and the overall team had to be downsized. These measures were intended to provide us with additional resources and runway to pursue further fundraising and revenue-generating opportunities. Despite continuous efforts, it has unfortunately become clear recently that the Venture Capital firms, and other strategic partners Triall was talking with will not be investing further in Triall. Furthermore, current shareholders have repeatedly loaned money to Triall, which we are unable to repay. This has resulted in considerable outstanding debt in the company, and a loss for each shareholder, leaving them unable to invest more.

It must be noted that the challenges we are facing are severe, and it is possible that the TRL token may lose (part of) its value. We understand that this news is upsetting, and our team will therefore be available to answer any questions that you might have.

We have always fully committed to making Triall a success and want to make it clear that
liquidity pools will not be touched by us and that The Triall Team and its core advisors will not be selling any tokens.

We are immensely grateful for your contributions and dedication to Triall over the past 2 years and hope for your understanding.

Kind regards,

The Triall Team

Triall Insights 🔍

Risk-Based Quality Management (RBQM) is on the rise.

Uniquely, RBQM applies the principles of risk-based monitoring to the entirety of a clinical trial, thereby promoting overall study quality & integrity.

According to a recent study by Tufts CSDD, 55% of sponsors and CROs report using RBQM in their clinical trials.

Of the survey respondents, 78% trust that RBQM improves study quality, while 64% believe RBQM increases efficiency & cost savings, and 53% trust it can reduce timelines.

🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1749405804455743930?s=20

#blockchainforhealth #TRL #DeSci

5 key areas for reporting & analytics in clinical trials 👩‍💻

eClinical tech continues to open up new avenues for reporting & analytics, promoting clinical trial quality, efficiency, and adaptability.

This includes reporting & analytics related to:
- Study performance metrics
- Informed consent
- Data management
- Audit & history
- Custom reports & integrations

Triall’s eClinical platform support all of these capabilities.

👇🧵In our latest Twitter thread we dive into the unique benefits this offers:
https://x.com/triallofficial/status/1747962160834056442?s=20

#blockchainforhealth #TRL #DeSci

Triall Insights 🔍

Late-stage clinical research has become increasingly complex.

According to Tufts CSDD, a typical Phase III clinical trial conducted during 2016-2021 collected an average of 25.8 endpoints.

This number is 37% higher compared to 2015, signalling a sharp increase in clinical trial complexity.

Around 25% of study procedures contributed to supporting secondary, tertiary, and exploratory endpoints.

Source: csdd.tufts.edu/impact-reports

🗣 Help spread the news on Twitter:
https://x.com/triallofficial/status/1746864959496048727?s=20

#blockchainforhealth #TRL #DeSci

Triall Insights 🔍

Are clinical trial participants undervalued?

Feedback from patients, sponsors, and sites across the globe underlines the importance of showing gratitude to trial participants.

Unfortunately, 1 in 3 participants do not feel valued for their contribution to clinical research, which can impact participant retention, satisfaction, and overall adherence.

TransCelerate has therefore developed The Gratitude Toolkit to incorporate best practices and address gaps along the clinical trial journey.

Source: transceleratebiopharmainc.com/assets/patientexperience/gratitude-toolkit/

🗣 Help spread the news on Twitter:
https://x.com/triallofficial/status/1744326412264157200?s=20

#blockchainforhealth #TRL #DeSci

5 automation capabilities in clinical trials 🤖

One of the most promising benefits of modern eClinical technology is their power to automate manual, time-consuming, and error-prone study tasks.

To illustrate, workflow automation can be applied in:
⁃ Review workflows
⁃ Direct data capture
⁃ Cross-form edit checks
⁃ Auto-validation
⁃ Payments

Triall’s eClinical platform support all of the above workflow automation capabilities.

👇🧵In our latest Twitter thread we dive into the unique benefits this offers:
https://x.com/triallofficial/status/1742518739998757194?s=20

#blockchainforhealth #TRL #DeSci

Future outlook: 5 key clinical trial trends in 2024 🧬

As we approach the end of the year it’s time to reflect and look ahead to what’s to come in 2024.

We expect the following industry trends to continue:
👉 Centralised -> Decentralised clinical trials
👉 Sponsor-centric -> Patient-centric clinical research
👉 Labour-driven -> Tech-driven operations
👉 Data management -> Data science & clinical informatics
👉 Traditional medicine -> Personalised medicine

👇🧵 Here we break down why these 5 trends will be important for #clinicaltrials and #DeSci next year:
https://x.com/triallofficial/status/1737428980129542528?s=20

#blockchainforhealth #TRL

Triall insights 🔍

Gratitude and appreciation take center stage during the holiday season, but these qualities are relevant in all domains of life—including clinical trials.

90% of clinical trial participants indicate that receiving an act of appreciation somewhat or greatly increased satisfaction.

Incorporating items that show gratitude & engage patients throughout the clinical trial journey can result in:
- Improved retention
- Better adherence
- Increased optimism throughout a study
- Increased trust in clinical research
- Improved relationship with clinical research staff

Source: transceleratebiopharmainc.com/assets/patientexperience/gratitude-toolkit/

🗣 Help us spread the news:
https://x.com/triallofficial/status/1736715072305582251?s=20

#blockchainforhealth #TRL

Partner Interview: CRO perspective on digital transformation 🖥️

Clinical trials are increasingly digital, decentralised, and data-heavy as the industry continues to adopt eConsent, ePRO, and wearable capabilities.

However, this digital transformation does not come without its challenges. Evolving regulations, system validation challenges, and internal change management are but some of the potential bottlenecks in digitalisation.

Embracing new technology is therefore not just about adopting the latest tools. It’s fundamentally about having the right team and processes in place.

A few months back, we spoke with Nick van den Bulk, Head of Clinical Operations at CR2O, to talk about the company’s successful journey towards digital transformation.

👉 Read the full interview: triall.io/articles/interview-a-cro-perspective-on-digital-transformation

🗣 Help spread the news:
https://x.com/triallofficial/status/1735615688805429291?s=20

#blockchainforhealth #TRL #DeSci

Product Spotlight: Triall AI 🤖

Electronic health records (EHRs) have long remained underutilised in clinical research.

Manual data entry of EHRs in the clinical trial database can quickly turn into an administrative burden for research sites who are often already short on time.

Our AI module automates this process using Machine Learning. It enables researchers to directly access, structure, and import EHR data into their database, transforming unstructured EHR data into structured EDC data entries.

This removes the need for manual and duplicate data entry, saving significant time and resources, all while reducing the chance of transcription errors.

👉 More products: triall.io/products/overview

🗣 Help us spread the news:
https://x.com/triallofficial/status/1734918934858490195?s=20

#blockchainforhealth #TRL #DeSci

Triall Insights 🔍

According to a survey by ISR, 89% of sponsors and CROs think their EDC system does not completely meet their needs for executing decentralised clinical trials.

Top unmet needs include:
(1) better data integration with ePRO, eConsent, and RTSM
(2) improved direct data capture from remote patients
(3) improved remote patient monitoring

Source: isrreports.com/future-of-edc-systems

🗣️ Help us spread the news:
https://x.com/triallofficial/status/1734184626749669834?s=20

#blockchainforhealth #TRL #DeSci

Building the Clinical Insights Exchange 📺

Triall’s CIX platform vision aims to redefine the boundaries of data-informed clinical research and #DeSci.

It allows clinical research professionals to tap into historical clinical trial data and unlock unique insights that inform study design, planning, and feasibility.

This video provides a sneak peek into the CIX catalogue, our SSI wallet for self-sovereign data ownership, and our virtual data assistant Triall GPT, a chat agent that runs on the GPT-4 LLM.

👉 Video link: https://youtu.be/fVJbdkXmcGc?si=9VDUubudF3_ZPVtl

🗣 Help spread the news:
https://x.com/triallofficial/status/1733105153278935166?s=20

#blockchainforhealth #TRL